Request Demo

Last update 08 May 2025

Lewis B antigen

Last update 08 May 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with Lewis B antigen

RebmAb300

Target

Lewis B antigen

Mechanism

Lewis B antigen inhibitors

Active Org.

Recepta Biopharma SA

Originator Org.

Recepta Biopharma SA

Active Indication

Carcinoma

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GNX1021

Target

Lewis B antigen x Lewis-Y antigen x Tubulin

Mechanism

Lewis B antigen inhibitors [+2]

Active Org.

GlycoNex, Inc.

Originator Org.

GlycoNex, Inc.

Active Indication

Stomach Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

58-1066 mAb

Target

Lewis B antigen

Mechanism

Lewis B antigen inhibitors

Active Org.

Recepta Biopharma SA

Originator Org.

Ludwig Institute for Cancer Research Ltd.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with Lewis B antigen

100 Translational Medicine associated with Lewis B antigen

0 Patents (Medical) associated with Lewis B antigen

Literatures (Medical) associated with Lewis B antigen

01 Feb 2025·Phytomedicine

Effect of daphnetin, the coumarin derivative isolated from Daphne genus, on Helicobacter pylori adhesion to gastric epithelial cells

Article

Author: Li, Zhongdong ; Sun, Qiang ; Wang, Mengjie ; You, Xuefu ; Wang, Genzhu ; Fan, Tianyun ; Pang, Jing

BACKGROUNDAdherence of Helicobacter pylori to the surface of the gastric mucosa is the initial and crucial step for its survival and colonization in the harsh conditions of the stomach. We had previously demonstrated that daphnetin has anti-adhesion effect.PURPOSEThis study aims to explore the mechanisms of daphnetin to reduce H. pylori adhesion to gastric epithelial cells (GES-1).METHODSFluorescence microscopy and urease assay were used to observe and validate the anti-adhesion effect of daphnetin. Terminal deoxynucleotidyl transferase dUTP nick end labeling, comet assay and agarose gel-based assay were conducted to evaluate the level of DNA damage. Quantitative real-time polymerase chain reaction, western blotting, electrophoretic mobility shifts assay and enzyme-linked immunosorbent assay were performed to investigate the mechanisms of the anti-adhesion effect of daphnetin.RESULTSOur results showed that daphnetin decreased H. pylori adhesion to GES-1 in time- and dose-dependent manners. The mechanisms by which daphnetin inhibits H. pylori adhesion involved the inducing of DNA double-strand breaks, the up-regulating of recA transcription leading to RecA binding at 1018-1597 site in the babA promoter, the decreasing of babA/babB transcription ratio, the decreasing of BabA expression and its interaction with Lewis b antigen.CONCLUSIONOur results suggested that daphnetin significantly inhibits H. pylori adhesion to GES-1 through the RecA-BabA pathway. To our knowledge, this is the first report on the mechanisms of daphnetin affecting H. pylori adhesion to GES-1.

01 Sep 2022·FEBS Open Bio

Lewis b antigen is a common ligand for genogroup I norovirus strains

Article

Author: Someya, Yuichi

Noroviruses are major causative agents of nonbacterial acute gastroenteritis in humans. Ten genogroups of noroviruses have been identified to date, among which genogroup I (GI) and genogroup II (GII) noroviruses are major pathogens for humans. GI and GII noroviruses are further classified into nine and 27 genotypes, respectively. Noroviruses are well known to bind to histo‐blood group antigens (HBGAs). Many studies have revealed that virus‐like particles (VLPs) from different genotypes exhibit distinct patterns of HBGA binding, but the assay conditions used in these studies were not identical. To enable comparison of the binding to HBGA of nine GI genotypes, I purified VLPs from insect cells and analysed their HBGA‐binding profiles. Although each genotype exhibited a distinct pattern of HBGA binding, Lewis b antigen was commonly recognized by all of the genogroup I strains, suggesting that this antigen plays a critical role in the pathogenesis of noroviruses.

01 Feb 2022·HelicobacterQ2 · MEDICINE

Helicobacterspecies binding to the human gastric mucosa

Q2 · MEDICINE

Article

Author: Haesebrouck, Freddy ; Matos, Rita ; Gärtner, Fátima ; Magalhães, Ana ; Amorim, Irina ; Nogueiro, Jorge ; Reis, Celso A. ; Sousa, Hugo Santos ; Carneiro, Fátima

AbstractHelicobacter pyloriinfects half of the world population, being associated with several gastric disorders, such as chronic gastritis and gastric carcinoma. TheHelicobactergenus also includes other gastric helicobacters, such asH.heilmannii¸ H.ailurogastricus,H.suis,H.felis,H.bizzozeronii, andH.salomonis. These gastric helicobacters colonize both the human and animal stomach. The prevalence of gastric non‐Helicobacter pylori Helicobacter(NHPH) species in humans has been described as low, and thein vitrobinding to the human gastric mucosa was never assessed. Herein, human gastric tissue sections were used for the evaluation of the tissue glycophenotype and for the binding of gastric NHPH strains belonging to different species. Histopathological evaluation showed that 37.5% of the patients enrolled in our cohort presented chronic gastritis, while the presence of neutrophil or eosinophilic activity (chronic active gastritis) was observed in 62.5% of the patients. The secretor phenotype was observed in 68.8% of the individuals, based on the expression of Lewis B antigen and binding of the UleX lectin. Thein vitrobinding assay showed that all the NHPH strains evaluated were able to bind, albeit in low frequency, to the human gastric mucosa. TheH.heilmannii,H.bizzozeronii, andH.salomonisstrains displayed the highest binding ability both to the gastric superficial epithelium and to the deep glands. Interestingly, we observed binding of NHPH to the gastric mucosa of individuals with severe chronic inflammation and intestinal metaplasia, suggesting that NHPH binding may not be restricted to the healthy gastric mucosa or slight chronic gastritis. Furthermore, thein vitrobinding of NHPH strains was observed both in secretor and non‐secretor individuals in a similar frequency. In conclusion, this study is the first report of thein vitrobinding ability of gastric NHPH species to the human gastric mucosa. The results suggest that other glycans, besides the Lewis antigens, could be involved in the bacterial adhesion mechanism; however, the molecular intervenients remain unknown.

News (Medical) associated with Lewis B antigen

27 Mar 2025

·www.prnewswire.com

GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025

Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on GNX1021 will be presented on April 28 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. GNX1021 is an antibody-drug conjugate (ADC) targeting branched Lewis B/Y (bLeB/Y), a unique tumor-associated glycan antigen overexpressed in gastric cancer and other solid tumors. The poster will highlight in vivo efficacy and safety findings from gastric cancer models that demonstrate GNX1021's tumor control activity. "We are very pleased that research involving GNX1021, our glycan-targeting ADC, was accepted for presentation at AACR 2025," said Dr. Mei-Chun Yang, CEO of GlycoNex. "AACR is one of the most influential oncology meetings in the world, and the opportunity to showcase the potential of GNX1021 to treat gastric cancer, an often-deadly cancer with few available therapies, highlights the importance of this program." Presentation Details: About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit . Contact s for GlycoNex, Inc. Investor Relations Tiberend Strategic Advisors, Inc. David Irish [email protected] Media Relations Eric Reiss [email protected] SOURCE GlycoNex, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AACRPhase 1ImmunotherapyADC

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lewis B antigen

Basic Info

Related

Analysis